<DOC>
	<DOCNO>NCT02229214</DOCNO>
	<brief_summary>The main purpose study measure effect VI-0521 kidney function . Specifically , glomerular filtration rate ( GFR ) measure baseline , 4 week study treatment , additional 4 week off-treatment recovery .</brief_summary>
	<brief_title>Effect VI-0521 ( Qsymia® ) Glomerular Filtration Rate ( GFR ) Overweight Obese Healthy Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , single-site study healthy overweight obese male female volunteer . Oral VI-0521 ( combination phentermine topiramate [ PHEN/TPM ] extended-release capsule ) administer daily follow : - Days 1-3 : PHEN/TPM 3.75 mg /23 mg - Days 4-6 : PHEN/TPM 7.5 mg /46 mg - Days 7-9 : PHEN/TPM 11.25 mg /69 mg - Days 10-28 : PHEN/TPM 15 mg /92 mg A single dose Iohexol ( non-radioactive iodine-containing contrast agent ) administer intravenously three separate occasion . The study include total 50 healthy subject ( 40 active 10 placebo ) , overnight stay 3 separate occasion . Total study duration approximately 10 week ( 2 week screen , 4 week study treatment , 4 week post treatment follow ) .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Key Male female 18 − 65 year age , medically healthy clinically significant screen abnormality BMI ≥27 ≤45 kg/m2 No use medication ( prescription , counter ( OTC ) herbal preparation ) exception contraception entirety study Key Allergy hypersensitivity radio contrast medium , iodine shellfish Plans significantly alter diet fasting , low caloric intake , elimination certain food ( gluten , milk , meat , etc . ) similar Plans undertake significant change physical exercise level ( i.e. , initiate training marathon ) study period Consumption high protein diet protein/body build meal supplementation and/or replacement . The use product contain creatine strictly prohibit History glaucoma increase intraocular pressure History bipolar disorder psychosis , history psychiatric hospitalization , great one lifetime episode major depression , current depression moderate great severity , presence history suicidal behavior ideation intent act Cholelithiasis ( gallstone ) within past 6 month History nephrolithiasis ( kidney stone ) Evidence clinically significant renal , pulmonary , hepatic , psychiatric condition history , physical examination laboratory study , opinion investigator , would contraindicate administration study medication , affect compliance , interfere study evaluation confound interpretation study result determine investigator Current use tobacco product include cigarette , cigar , pipe , chew tobacco , nicotine replacement product ( e.g. , patch , gum , lozenge , etc . ) , chronic use within previous three month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Renal function</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Kidney function</keyword>
	<keyword>Qsymia</keyword>
	<keyword>Iohexol</keyword>
	<keyword>Serum Creatinine</keyword>
	<keyword>Creatinine clearance</keyword>
	<keyword>Renal Clearance</keyword>
	<keyword>VI-0521</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>